Can a targeted pill boost standard therapy for hard-to-treat leukemia?

NCT ID NCT06652438

Disease control Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Sep 03, 2026 · Updated 6 times

Summary

This phase 3 trial is testing whether adding revumenib, a drug that blocks a protein called menin, to the usual two-drug combination (azacitidine and venetoclax) can improve outcomes for adults newly diagnosed with acute myeloid leukemia (AML) that has a specific genetic change (NPM1 mutation or KMT2A rearrangement). The study enrolls people who are not healthy enough for intensive chemotherapy. Participants are randomly assigned to receive either revumenib or a placebo alongside standard treatment, and researchers will track survival and remission rates over several years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: revumenib added to azacitidine and venetoclax
What this could lead to: If successful, this could lead to a more effective treatment option for people with certain genetic types of AML who cannot tolerate intensive chemotherapy.
What could go wrong: This is an early-phase trial, and the added drug may cause more side effects or fail to improve survival. Results will take years to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 448 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Aug 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: In order to be eligible to participate in this study, a patient must meet all of the following criteria: 1. Patient with newly diagnosed NPM1-mutated AML, consistent with NPM1c, according to the 2022 International Consensus Classification (i.e. ≥ 10% blasts). OR Patient with newly diagnosed KMT2A-rearranged AML according to the 2022 International Consensus Classification (i.e. ≥ 10% blasts). KMT2A partial tandem duplications or deletions are NOT eligible. Of note: in case both NPM1 and IDH1 are mutated and both EVOLVE-1 (HO173) and EVOLVE-2 (HO177) are open for inclusion at your site, then patients can only be included in the EVOLVE-1 trial (HO173) 2. Central confirmation of NPM1 mutation or KMT2A rearrangement in one of the dedicated central genetic laboratories. 3. Age ≥ 18 years, no upper age limit. 4. Patient is ineligible for intensive induction chemotherapy by meeting at least 1 of the following criteria: * ≥ 75 years of age: ineligible for intensive chemotherapy per physician's discretion (with an ECOG performance status 0-2) . * 18-74 years: patient is not eligible for standard chemotherapy because any of the following co-morbidities: * ECOG performance status 2 or 3 . * Cardiac history of chronic heart failure requiring treatment; or with an ejection fraction ≤50%; or chronic stable angina. * DLCO ≤ 65% or FEV1 ≤ 65%. * Creatinine clearance ≥ 30 mL/min to \<45 ml/min calculated by the Cockcroft Gault formula. * Moderate hepatic impairment with total bilirubin \> 1.5 to \< 3.0 x upper limit of normal (ULN). * Any other comorbidity that the local physician assesses to be incompatible with intensive chemotherapy must be reviewed and approved by the Sponsor's (co-) Principal Investigator (written approval must be sent to [email protected] before study enrolment). 5. Patient must have a projected life expectancy of at least 12 weeks (as assessed by the treating physician). 6. Patient must have a white cell blood (WBC) count of \< 25 x 109/L. Hydroxyurea can be used prior to study enrolment to reduce the WBC count to meet this criterion. 7. Adequate renal function as evidenced by serum creatinine ≤ 2.0 × upper limit of norm (ULN) or creatinine clearance \>30 mL/min based on the Cockcroft-Gault glomerular filtration rate (GFR). 8. Adequate hepatic function as evidenced by: * Serum total bilirubin ≤ 3.0 × ULN unless considered due to Gilbert's disease, or leukemic involvement following written approval by the sponsor (Co-)Principal Investigator (copy in [email protected]). * Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 3.0 × ULN, unless considered due to leukemic involvement following written approval by the sponsor (Co-)Principal Investigator (copy in [email protected]). 9. Female patient must: * be of nonchildbearing potential: o postmenopausal (defined as at least 1 year without any menses). o documented surgically sterile (e.g. documented hysterectomy, bilateral oophorectomy, bilateral salpingectomy or congenital sterile) or status post hysterectomy (at least 1 month prior to screening). * or, if of childbearing potential (not surgically sterile and not postmenopausal) agree to avoid pregnancy during the study and for 6 months after the final study drug administration. * and have a negative urine or serum pregnancy test at screening. * and, if heterosexually active, agree to consistently apply one highly effective\* method of birth control in combination to a barrier method for the duration of the study and for 6 months after the final study drug administration. \*Highly effective forms of birth control include \- Consistent and correct usage of established hormonal contraceptives that inhibit ovulation for at least 1 month prior to taking study drug. (hormonal contraception is only a highly effective method of birth control, if a combined \[estrogen and progestogen containing\] hormonal contraception or a progestogen-only hormonal contraception - both associated with inhibition of ovulation - is used. \- Established intrauterine device (IUD) or intrauterine system (IUS) \- Bilateral tubal occlusion \- Vasectomy - a vasectomy is highly effective contraception method provided the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. \- Male is sterile due to a bilateral orchiectomy. * Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual activity during the entire period of risk associated with the study drug. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. List is not all inclusive. Prior to enrolment, the investigator is responsible for confirming patient will utilize highly effective forms of birth control in combination with a barrier method according to locally accepted standards during the protocol defined period. * agree not to breastfeed starting at screening and throughout the study period. * agree not to donate ova starting at screening and throughout the study period, and for 6 months after the final study drug administration. 10. Men must use a latex condom during any sexual contact with women of childbearing potential (WOCBP), even if they have undergone a successful vasectomy and must agree to avoid to father a child (while on therapy and for 6 months after the final study drug administration). In addition, their female partners of childbearing potential must use a highly effective method of birth control. 11. Male patient must not donate sperm starting at screening and throughout the study period and for 6 months after the final study drug administration. 12. Able to understand and willing to sign an informed consent form (ICF). 13. Institutional Review Board/Independent Ethics Committee-approved written informed consent as per national regulations must be obtained from the patient prior to any study-related procedures (including consent for withdrawal of prohibited medication, if applicable). Exclusion Criteria: Subject has previously been treated for AML; a treatment period with hydroxyurea to control WBC counts is allowed; prior treatment with a hypomethylating agent for MDS-EB is not allowed; prior treatment with erythropoiesis-stimulating agents or luspatercept for MDS is allowed. 2\. Acute promyelocytic leukemia (APL) with t(15;17)(q24.1;q21.2); PML-RARA; or one of the other pathognomonic variant chromosomal translocations / fusion genes. 3. AML with BCR-ABL1; or myeloid blast crisis of CML. 4. Significant active cardiac disease within 3 months prior to the start of study treatment, including: * New York Heart Association (NYHA) class III or IV congestive heart failure * Myocardial infarction * Unstable angina * Severe cardiac arrhythmias * Congenital long QT syndrome of family member with this condition QTcF \>450 msec on screening electrogram for males and \>470msec on screening electrogram for females (mean of triplicate recordings; calculated using Fridericia's correction). 5. Severe obstructive or restrictive ventilation disorder. 6. History of stroke or intracranial hemorrhage within 6 months prior to randomization. 7\. Clinical symptoms suggestive of active central nervous system (CNS) leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid (CSF) during screening is only required if there is a clinical suspicion of CNS involvement by leukemia during screening. 8. Active infection, including hepatitis B or hepatitis C or Human Immunodeficiency Virus (HIV) infection, that is uncontrolled prior to first dose of study treatment and may interfere with the study objectives or which could expose the patient to undue risk through the participation in the clinical trial; an infection controlled with an approved antibiotic/ antiviral/ antifungal treatment that is not a strong or moderate CYP3A inducer is allowed. Patients with COVID-19 infection can be enrolled, if the patient has no symptoms and was tested negative twice by PCR test prior to inclusion in the trial. 9. Immediate life-threatening, severe complications of leukemia such as uncontrolled bleeding and/or disseminated intravascular coagulation. 10. Conditions that limit the ingestion or gastrointestinal absorption of orally administered drugs. 11\. Patient with a currently active second malignancy. Patients are not considered to have a currently active malignancy, if they have completed therapy and are considered by their physician to be at \< 30% risk of relapse within one year. However, patients with the following history/concurrent conditions are allowed: * Basal or squamous cell carcinoma of the skin; * Carcinoma in situ of the cervix; * Carcinoma in situ of the breast; * Incidental histologic finding of prostate cancer. 12. Receipt of live, attenuated vaccine within 30 days prior to the study inclusion (NOTE: patient, if enrolled, should not receive live vaccine during the study and until 6 months after the therapy). 13\. Severe neurological or psychiatric disorder interfering with ability to give an informed consent. 14\. Contraindication to AZA or VEN (as per Summary of Product Characteristics (SmPC)). 15\. Patient weighing \<40 kg at registration. 16. Participation in other prospective studies with anti-leukemic and/or investigational agents. 17\. Patient taking Dabigatran unless they can be transferred to other medications within ≥5 half-lives prior to dosing. Patients taking other P-gP transporter-sensitive medications (see Appendix H) should be properly monitored during the study if they cannot be transferred to other medications. 18\. Patient taking known strong cytochrome P450 (CYP) 3A4 inducers (see Appendix G), unless they can be transferred to other medications within ≥5 half-lives prior to dosing. 19\. The patient is a pregnant or lactating woman, or plans to become pregnant during the study. 20\. Patient who has once been screened and randomized into this HO177 trial but was considered ineligible cannot re-enter this trial at a later date.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia acute myeloid leukemia with mutated NPM1 acute myeloid leukemia, MLL gene rearrangement

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myeloid leukemia, adult

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

200 sites in 18 countries. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

AT-Feldkirch-IKHF
RECRUITING

Feldkirch, Austria
AT-Linz-KEPLER
NOT_YET_RECRUITING

Linz, Austria
AT-Salzburg-SALK
NOT_YET_RECRUITING

Salzburg, Austria
AT-Vienna-HANUSCH
RECRUITING

Vienna, Austria
AU-Adelaide-RAH
NOT_YET_RECRUITING

Adelaide, Australia
AU-Birtinya-SUNSHINECOASTUH General Information
NOT_YET_RECRUITING

Birtinya, Australia
AU-Brisbane-RBWH
RECRUITING

Brisbane, Australia
AU-Douglas-TOWNSVILLE
NOT_YET_RECRUITING

Douglas, Australia
AU-Melbourne-ALFRED
RECRUITING

Melbourne, Australia
AU-Melbourne-MONASH
NOT_YET_RECRUITING

Melbourne, Australia
AU-Perth-FSH
WITHDRAWN

Perth, Australia
AU-Perth-SCGH
NOT_YET_RECRUITING

Perth, Australia
AU-Sydney-RNSH
NOT_YET_RECRUITING

Sydney, Australia
AU-Sydney-SVSH
NOT_YET_RECRUITING

Sydney, Australia
Amsterdamumc
RECRUITING

Amsterdam, Netherlands
BE-Antwerpen-ZAS
RECRUITING

Antwerp, Belgium
BE-Brugge-AZBRUGGE
RECRUITING

Bruges, Belgium
BE-Brussel-BORDET
RECRUITING

Brussels, Belgium
BE-Brussel-UZBRUSSEL
RECRUITING

Brussels, Belgium
BE-Bruxelles-STLUC
RECRUITING

Brussels, Belgium
BE-Gent-UZGENT
RECRUITING

Ghent, Belgium
BE-Hasselt-VIRGAJESSE
NOT_YET_RECRUITING

Hasselt, Belgium
BE-Leuven-UZLEUVEN
RECRUITING

Leuven, Belgium
BE-Liege-CHULIEGE
RECRUITING

Liège, Belgium
BE-Yvoir-MONTGODINNE
RECRUITING

Yvoir, Belgium
Beatson West of Scotland Cancer Centre
RECRUITING

Glasgow, United Kingdom
Belfasttrust
NOT_YET_RECRUITING

Belfast, United Kingdom
Birmingham-QE
NOT_YET_RECRUITING

Birmingham, United Kingdom
Blackpool Victoria
RECRUITING

Blackpool, United Kingdom
CH-Aarau-KSA
RECRUITING

Aarau, Switzerland
CH-Basel-USB
RECRUITING

Basel, Switzerland
CH-Bellinzona-IOSI
RECRUITING

Bellinzona, Switzerland
CH-Bern-INSEL
RECRUITING

Bern, Switzerland
CH-Geneve (14)-HCUGE
RECRUITING

Geneva, Switzerland
CH-Zürich-USZ
NOT_YET_RECRUITING

Zurich, Switzerland
Christie NHS Foundation Trust
RECRUITING

Manchester, United Kingdom
Churchill Hospital, Oxford
RECRUITING

Oxford, United Kingdom
DE-Berlin-CAMPUSBENFRANKLIN
NOT_YET_RECRUITING

Berlin, Germany
DE-Berlin-CAMPUSVIRCHOW
NOT_YET_RECRUITING

Berlin, Germany
DE-Berlin-VIVANTESNEUKOLLN
NOT_YET_RECRUITING

Berlin, Germany
DE-Bochum-RUB
RECRUITING

Bochum, Germany
DE-Bonn-UNIBONN
NOT_YET_RECRUITING

Bonn, Germany
DE-Braunschweig-KLINIKUMBRAUNSCHWEIG
NOT_YET_RECRUITING

Braunschweig, Germany
DE-Bremen-KBM
NOT_YET_RECRUITING

Bremen, Germany
DE-Darmstadt-KLINIKUMDARMSTADT
NOT_YET_RECRUITING

Darmstadt, Germany
DE-Essen-KEM
NOT_YET_RECRUITING

Essen, Germany
DE-Flensburg-MALTESER
RECRUITING

Flensburg, Germany
DE-Freiburg-UNIKLINIKFREIBURG
NOT_YET_RECRUITING

Freiburg im Breisgau, Germany
DE-Greifswald-UNIGREIFSWALD
RECRUITING

Greifswald, Germany
DE-Hamburg-ASKLEPIOSSTGEORG
RECRUITING

Hamburg, Germany
DE-Hamburg-UKE
NOT_YET_RECRUITING

Hamburg, Germany
DE-Hannover-MHHANNOVER
RECRUITING

Hanover, Germany
DE-Heilbronn-SLK General Information
RECRUITING

Heilbronn, Germany
DE-Herne-MARIENHOSPITALHERNE
RECRUITING

Herne, Germany
DE-Karlsruhe-KLINIKUMKARLSRUHE
NOT_YET_RECRUITING

Karlsruhe, Germany
DE-Magdeburg-OVGU
RECRUITING

Magdeburg, Germany
DE-Mainz-UNIMEDIZINMAINZ
RECRUITING

Mainz, Germany
DE-Minden-MUEHLENKREISKLINKEN
NOT_YET_RECRUITING

Minden, Germany
DE-München-IRZTUM
NOT_YET_RECRUITING

München, Germany
DE-Oldenburg-KLINIKUMOLDENBURG
RECRUITING

Oldenburg, Germany
DE-Potsdam-BERGMANN
NOT_YET_RECRUITING

Potsdam, Germany
DE-Regensburg-UKR
NOT_YET_RECRUITING

Regensburg, Germany
DE-Rostock-MUROSTOCK
NOT_YET_RECRUITING

Rostock, Germany
DE-Stuttgart-KLINIKUMSTUTTGART
NOT_YET_RECRUITING

Stuttgart, Germany
DE-Tübingen-MEDUNITUEBINGEN
NOT_YET_RECRUITING

Tübingen, Germany
DE-Ulm-UNIKLINKULM
RECRUITING

Ulm, Germany
DE-Wuppertal-HELIOSGESUNDHEIT
NOT_YET_RECRUITING

Wuppertal, Germany
DK-Aalborg-AALBORGUH
NOT_YET_RECRUITING

Aalborg, Denmark
DK-Aarhus N-AUH
RECRUITING

Aarhus N, Denmark
DK-Copenhagen-RIGSHOSPITALET
NOT_YET_RECRUITING

Copenhagen, Denmark
DK-Odense-OUH
NOT_YET_RECRUITING

Odense, Denmark
EE-Tallinn-REGIONAALHAIGLA
RECRUITING

Tallinn, Estonia
EE-Tartu-TARTU
RECRUITING

Tartu, Estonia
ES-Alicante-BALMIS
NOT_YET_RECRUITING

Alicante, Spain
ES-Barcelona-CLINICUB
RECRUITING

Barcelona, Spain
ES-Barcelona-GERMANTRIALS
RECRUITING

Barcelona, Spain
ES-Barcelona-ICODURANREYNALS
RECRUITING

Barcelona, Spain
ES-Barcelona-MUTUATERRASSA
RECRUITING

Barcelona, Spain
ES-Barcelona-PARCDESALUTMAR
RECRUITING

Barcelona, Spain
ES-Barcelona-SANTPAU
RECRUITING

Barcelona, Spain
ES-Girona-ICOGIRONA
RECRUITING

Girona, Spain
ES-Lleida-ICSVILANOVA
RECRUITING

Lleida, Spain
ES-Madrid-CSGREGORIOMARANON
RECRUITING

Madrid, Spain
ES-Palma-SSIB
RECRUITING

Palma de Mallorca, Spain
ES-Tarragona-JOAN
RECRUITING

Tarragona, Spain
ES-Valencia-MALVARROSA
RECRUITING

Valencia, Spain
FI-Helsinki-HUS
RECRUITING

Helsinki, Finland
FI-Oulu-OYS
RECRUITING

Oulu, Finland
FI-Tampere-TAYS
RECRUITING

Tampere, Finland
FI-Turku-TYKS
RECRUITING

Turku, Finland
FR-Amiens-CHUAMIENS
NOT_YET_RECRUITING

Amiens, France
FR-Angers-CHUANGERS
RECRUITING

Angers, France
FR-Bayonne-CHCOTEBASQUE
NOT_YET_RECRUITING

Bayonne, France
FR-Besançon Cedex-JEANMINJOZ
NOT_YET_RECRUITING

Besançon, France
FR-Caen-CHUCAEN
RECRUITING

Caen, France
FR-Clamart-HIAPERCY
RECRUITING

Clamart, France
FR-Clermont Ferrand-ESTAING
NOT_YET_RECRUITING

Clermont-Ferrand, France
FR-Créteil cedex-CHUMONDOR
RECRUITING

Créteil, France
FR-Grenoble cedex 9-CHUGRENOBLE
RECRUITING

Grenoble, France
FR-Le Chesnay cedex-CHVERSAILLES
NOT_YET_RECRUITING

Le Chesnay, France
FR-Lille-CHULILLE
NOT_YET_RECRUITING

Lille, France
FR-Limoges-CHULIMOGES
NOT_YET_RECRUITING

Limoges, France
FR-Lyon Pierre Benite cedex-LYONSUD
RECRUITING

Pierre-Bénite, France
FR-Metz-Cedex-MERCY
RECRUITING

Metz, France
FR-Montpellier-STELOI
RECRUITING

Montpellier, France
FR-Nantes-CHUNANTES
NOT_YET_RECRUITING

Nantes, France
FR-Nice-LARCHET
RECRUITING

Nice, France
FR-Pessac Cedex-CHUBORDEAUX
RECRUITING

Pessac, France
FR-Rouen cedex-BECQUEREL
NOT_YET_RECRUITING

Rouen, France
FR-Saint-Priest-en-Jarez-STETIENNE
RECRUITING

Saint-Priest-en-Jarez, France
FR-Strasbourg cedex-HAUTEPIERRE
NOT_YET_RECRUITING

Strasbourg, France
Halle-UMH
RECRUITING

Halle, Germany
IE-Cork-CUH
RECRUITING

Cork, Ireland
IE-Dublin 4-SVUH
RECRUITING

Dublin, Ireland
IE-Dublin 7-MATER
RECRUITING

Dublin, Ireland
IE-Dublin 8-STJAMES
RECRUITING

Dublin, Ireland
IE-Dublin 9-BEAUMONT
RECRUITING

Dublin, Ireland
IE-Galway-UHGALWAY
RECRUITING

Galway, Ireland
IE-Waterford City-WATERFORD
RECRUITING

Waterford, Ireland
IT-Ancona-MARCHE
RECRUITING

Ancona, Italy
IT-Bologna-MALPHIGI
NOT_YET_RECRUITING

Bologna, Italy
IT-Civitanova Marche-AZURZONA
NOT_YET_RECRUITING

Civitanova Marche, Italy
IT-Milano-NIGUARDA
NOT_YET_RECRUITING

Milan, Italy
IT-Pagani-TORTORA
NOT_YET_RECRUITING

Pagani, Italy
IT-Palermo-CERVELLO
NOT_YET_RECRUITING

Palermo, Italy
IT-Perugia-OSPEDALEPERUGIA
NOT_YET_RECRUITING

Perugia, Italy
IT-Pescara-AUSLPESCARA
NOT_YET_RECRUITING

Pescara, Italy
IT-Roma-SAPIENZA
NOT_YET_RECRUITING

Roma, Italy
IT-Roma-TORVERGATA
NOT_YET_RECRUITING

Roma, Italy
IT-Torino-CITTADELLASALUTE
NOT_YET_RECRUITING

Torino, Italy
IT-Trieste-MAGGIORETRIESTE
NOT_YET_RECRUITING

Trieste, Italy
King's College Hospital
RECRUITING

London, United Kingdom
LT-Vilnius-SANTA
RECRUITING

Vilnius, Lithuania
NL-Amersfoort-MEANDERMC
RECRUITING

Amersfoort, Netherlands
NL-Amsterdam-OLVG
RECRUITING

Amsterdam, Netherlands
NL-Arnhem-RIJNSTATE
RECRUITING

Arnhem, Netherlands
NL-Breda-AMPHIA
RECRUITING

Breda, Netherlands
NL-Delft-RDGG
RECRUITING

Delft, Netherlands
NL-Den Bosch-JBZ
RECRUITING

's-Hertogenbosch, Netherlands
NL-Den Haag-HAGA
RECRUITING

The Hague, Netherlands
NL-Dordrecht-ASZ
RECRUITING

Dordrecht, Netherlands
NL-Dordrecht-ASZ
RECRUITING

Dordrecht, Netherlands
NL-Eindhoven-MAXIMAMC
RECRUITING

Eindhoven, Netherlands
NL-Enschede-MST
RECRUITING

Enschede, Netherlands
NL-Goes-ADRZ
RECRUITING

Goes, Netherlands
NL-Groningen-UMCG
RECRUITING

Groningen, Netherlands
NL-Leeuwarden-FRISIUSMC
RECRUITING

Leeuwarden, Netherlands
NL-Leiden-LUMC
RECRUITING

Leiden, Netherlands
NL-Maastricht-MUMC
RECRUITING

Maastricht, Netherlands
NL-Nieuwegein-ANTONIUS
RECRUITING

Nieuwegein, Netherlands
NL-Nijmegen-RADBOUDUMC
RECRUITING

Nijmegen, Netherlands
NL-Rotterdam-ERASMUSMC
RECRUITING

Rotterdam, Netherlands
NL-Utrecht-UMCUTRECHT
RECRUITING

Utrecht, Netherlands
NL-Zwolle-ISALA
RECRUITING

Zwolle, Netherlands
NO-Bergen-HELSEBERGEN
RECRUITING

Bergen, Norway
NO-Drammen-VESTREVIKEN
RECRUITING

Drammen, Norway
NO-Lørenskog-AKERSHUS
RECRUITING

Lørenskog, Norway
NO-Oslo-OSLOUH
RECRUITING

Oslo, Norway
NO-Stavanger-HELSESTAVANGER
RECRUITING

Stavanger, Norway
NO-Tromsø-NORTHNOORWEGEN
NOT_YET_RECRUITING

Tromsø, Norway
NO-Trondheim-STOLAV
RECRUITING

Trondheim, Norway
New cross hospital wolverhampton
RECRUITING

Wolverhampton, United Kingdom
Nottingham University Hospitals NHS Trust
RECRUITING

Nottingham, United Kingdom
SE-Goteborg-SAHLGRENSKA
RECRUITING

Gothenburg, Sweden
SE-Lund-SUH
RECRUITING

Lund, Sweden
SE-Stockholm-KAROLINSKAHUDDINGE
NOT_YET_RECRUITING

Stockholm, Sweden
SE-Uppsala-UPPSALAUH
RECRUITING

Uppsala, Sweden
Southampton General Hospital
RECRUITING

Southampton, United Kingdom
St Bartholomew's Hospital
RECRUITING

London, United Kingdom
St. James UH
RECRUITING

Leeds, United Kingdom
The Newcastle upon Tyne Hospitals NHS Foundation Trust
RECRUITING

Newcastle, United Kingdom
The Royal Marsden NHSFT
RECRUITING

Sutton, United Kingdom
UK-Bodelwyddan-BCUHB
NOT_YET_RECRUITING

Bodelwyddan, United Kingdom
UK-Bristol-BRISTOLCENTRE
RECRUITING

Bristol, United Kingdom
UK-Cornwall-RCH
RECRUITING

Truro, United Kingdom
UK-Coventry-UHCOVENTRYANDWARWICKSHIRE
RECRUITING

Coventry, United Kingdom
UK-Derby-ROYALDERBYHOSPITAL
NOT_YET_RECRUITING

Derby, United Kingdom
UK-Edinburgh-WGH
NOT_YET_RECRUITING

Edinburgh, United Kingdom
UK-Harrow-NORTHWICK
NOT_YET_RECRUITING

Harrow, United Kingdom
UK-Hull-CASTLEHILL
RECRUITING

Hull, United Kingdom
UK-Manchester-ROYALINFIRMARY
RECRUITING

Manchester, United Kingdom
UK-Portsmouth-QUEENALEXANDRA
RECRUITING

Cosham, United Kingdom
UK-Stoke on Trent-UHNM
NOT_YET_RECRUITING

Stoke-on-Trent, United Kingdom
UK-Swindon-GWH
NOT_YET_RECRUITING

Swindon, United Kingdom
US-Atlanta GA-EMORY
RECRUITING

Atlanta, Georgia, 30322, United States
US-Baltimore MD-UMGCCC
RECRUITING

Baltimore, Maryland, 21201, United States
US-Chapel Hill-UNCNORTHCAROLINA
RECRUITING

Chapel Hill, North Carolina, 27514, United States
US-Cincinnati OH-CINCY
RECRUITING

Cincinnati, Ohio, 45219, United States
US-Colombus OH-OSU
RECRUITING

Columbus, Ohio, 43210, United States
US-Dallas TX-SOUTHWESTERN
NOT_YET_RECRUITING

Dallas, Texas, 75390, United States
US-Jacksonville FL-MAYOFL
NOT_YET_RECRUITING

Jacksonville, Florida, 32224, United States
US-Kansas City KS-KUMC
NOT_YET_RECRUITING

Fairway, Kansas, 66205, United States
US-Los Angeles CA-UCLA
NOT_YET_RECRUITING

Los Angeles, California, 90095, United States
US-Pittsburgh PA-PITT
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
US-Portland OR-OHSU
NOT_YET_RECRUITING

Portland, Oregon, 97239, United States
US-Rochester MN-MAYOMN
NOT_YET_RECRUITING

Rochester, Minnesota, 55905, United States
US-San Francisco CA-UCSF
NOT_YET_RECRUITING

San Francisco, California, 94143, United States
US-Wheeling WV-WVU
RECRUITING

Wheeling, West Virginia, 26003, United States
University College Hospital
RECRUITING

London, United Kingdom
University Hospital of Wales
RECRUITING

Cardiff, United Kingdom
University Hospitals of Leicester NHS Trust
RECRUITING

Leicester, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.